Alnylam Pharmaceuticals
ALNY
#619
Rank
โ‚น3.975 T
Marketcap
โ‚น29,777
Share price
3.68%
Change (1 day)
4.99%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): โ‚น346.28

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น360.81. In 2025 the company made an earnings per share (EPS) of โ‚น171.36.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น346.28102.08%
2025โ‚น171.36
2023-โ‚น336.06-62%
2022-โ‚น884.4129.03%
2021-โ‚น685.44-3.36%
2020-โ‚น709.24-8.48%
2019-โ‚น774.937.67%
2018-โ‚น719.7139.74%
2017-โ‚น515.0312.94%
2016-โ‚น456.0138.84%
2015-โ‚น328.44-32.88%
2014-โ‚น489.33259.44%
2013-โ‚น136.14-31.25%
2012-โ‚น198.02

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น668.30 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น243.68-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น4,049 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น792.06-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น69.50-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น22.85-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น130.42-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น33.32-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA